Publications by authors named "A Albasanz-Puig"
Chimeric antigen receptor (CAR) T cells targeting CD19 have changed the treatment landscape of patients with relapsed/refractory diffuse large B-cell lymphoma. Infections are one of the most frequent complications after CAR T-cell therapy. Most of these infections are bacterial, although viral infections can also occur in this setting.
View Article and Find Full Text PDFData are scarce on cytomegalovirus (CMV) replication in patients receiving CD19-directed chimeric antigen receptor (CAR) T cell treatment. Here we describe the incidence, severity, and management of CMV infection in patients with aggressive B cell lymphoma treated with CAR T cell therapy. In this retrospective observational study, we analyzed CMV viral load and its clinical impact in patients with aggressive B cell lymphoma receiving CAR T cell therapy between July 2018 and December 2021 at a single center.
View Article and Find Full Text PDFArticle Synopsis
- The study assessed the impact of ceftolozane-tazobactam (C/T) treatment on mortality and mechanical ventilation needs in neutropenic hematologic patients with Pseudomonas aeruginosa bloodstream infections (PA BSI), comparing it to other antibiotic treatments.
- Out of 132 patients analyzed, a significant majority (91%) had multidrug-resistant PA strains, with pneumonia and endogenous sources being the most common origins for BSI.
- Results showed that C/T treatment significantly reduced the need for mechanical ventilation and lowered both 7-day and 30-day mortality rates compared to alternative antibiotics in this vulnerable patient population.
To assess the effect of combination antibiotic empirical therapy on 30-day case-fatality rate in neutropenic cancer patients with Pseudomonas aeruginosa (PA) bacteremic pneumonia. This was a multinational, retrospective cohort study of neutropenic onco-hematological patients with PA bloodstream infection (BSI) (2006−2018). The effect of appropriate empirical combination therapy, appropriate monotherapy and inappropriate empirical antibiotic therapy [IEAT] on 30-day case-fatality was assessed only in patients with PA bacteremic pneumonia.
View Article and Find Full Text PDF